Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma CEO Pablo G. Legorreta acquired 157,828 Class A Ordinary Shares at $0.00 per share on February 11, 2026 through the settlement of equity performance awards. Following this exempt award, he directly holds 1,098,783 Class A Ordinary Shares.
He also has indirect ownership through various family trusts and entities, including Legorreta Children 2002 Trust, GST-Exempt Legorreta family trusts, Legorreta Investments LLC, Tata MC 35 Ltd., and accounts for spouse and children. In addition, he and related vehicles hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 73,495,660 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 13,356,742 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.
Royalty Pharma plc executive vice president and CFO Terrance P. Coyne reported an indirect equity award of Class A Ordinary Shares. On February 11, 2026, an affiliated entity, TPC RP EPA1 LLC, acquired 26,626 Class A shares at $0 per share in an exempt transaction under Rule 16b-3 tied to the settlement of equity performance awards. Following this grant, TPC RP EPA1 LLC holds 49,511 Class A shares indirectly for Coyne. The filing also notes additional indirect holdings through related LLCs and retirement accounts, plus partnership and Class E Ordinary Share interests exchangeable into 6,448,180 and 1,807,277 Class A shares, respectively, with the Class E interests subject to vesting conditions.
Royalty Pharma plc EVP & Vice Chairman Christopher Hite reported an indirect acquisition of 26,626 Class A Ordinary Shares on February 11, 2026. The shares were granted at $0 per share in an exempt equity award settlement under Rule 16b-3.
After this transaction, 685,136 Class A Ordinary Shares are held indirectly through SCH Investment Partners LLC, and 70,000 Class A Ordinary Shares are held directly. In addition, family vehicles hold interests exchangeable into 866,410 Class A shares and Class E shares exchangeable into 1,238,789 Class A shares, with the Class E shares subject to vesting conditions.
Royalty Pharma plc EVP Marshall Urist reported an exempt acquisition of 19,970 Class A Ordinary Shares on February 11, 2026. The shares were granted at a price of $0.00 in connection with the settlement of equity performance awards, increasing his directly held Class A stake to 27,368 shares. In addition, 19,020 Class A Ordinary Shares are held indirectly through an IRA, highlighting a mix of direct and retirement-account ownership tied to his role as EVP, Research & Investments.
Royalty Pharma plc is the largest buyer of biopharmaceutical royalties, funding innovation by purchasing interests in drug sales from academic, biotech and large pharma partners. Its portfolio spans royalties on more than 35 marketed therapies and 20 development-stage product candidates.
In 2025, the company generated $3.3 billion of Portfolio Receipts, mainly cash flows from existing royalty investments, and announced transactions with total potential value of $4.7 billion, deploying $2.6 billion of cash into new royalties and related assets. The portfolio includes 16 therapies each with over $1 billion in 2025 end‑market sales, providing diversified exposure across rare disease, oncology, neuroscience, immunology and other areas.
Royalty Pharma emphasizes long-duration cash flows, selective capital deployment and a flexible structuring toolkit, including third‑party royalties, synthetic royalties and other funding arrangements. Key risks center on product sales performance, development‑stage failures, competition for royalties, leverage, and regulatory and market uncertainties in the global biopharmaceutical sector.
Royalty Pharma plc reported strong growth for Q4 and full year 2025 and issued 2026 guidance. Portfolio Receipts rose 18% in Q4 2025 to $874 million and 16% for 2025 to $3,254 million, while Royalty Receipts grew 13% to $3,127 million, led by Voranigo, Trelegy, Tremfya and the cystic fibrosis franchise.
Adjusted EBITDA increased 16% to $2,966 million and Portfolio Cash Flow rose 11% to $2,724 million in 2025, though net cash from operating activities declined to $2,490 million from $2,769 million. The company deployed $2.6 billion on royalty transactions and repurchased 37 million shares for $1.2 billion, alongside $512 million of dividends, supported by $619 million of cash and $9.2 billion of debt at year-end.
For 2026, Royalty Pharma expects Portfolio Receipts of $3,275 million to $3,425 million, implying Royalty Receipts growth of 3% to 8%, with lower operating and professional costs as a percentage of Portfolio Receipts following the internalization of its external manager and interest paid projected at $350 million to $360 million.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported indirect sales of Class A Ordinary Shares through entities associated with him. Between February 2 and 4, 2026, TPC RP 2021, LLC and TPC RP EPA1 LLC sold multiple share blocks at weighted average prices around $42–$43 per share, with detailed price ranges disclosed in footnotes. All sales were made under a Rule 10b5-1 trading plan adopted on August 8, 2025. The filing also lists remaining indirect holdings in family vehicles and IRAs, direct holdings, and additional partnership and Class E interests exchangeable into Class A Ordinary Shares, with certain Class E shares subject to vesting conditions.
A shareholder in RPRX has filed a Form 144 notice to sell up to 135,117 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $5,805,977.49. The notice lists 427,247,489 shares outstanding and targets an approximate sale date of February 3, 2026 on NASD.
The shares to be sold were acquired from the issuer in a private transaction on June 16, 2020 and as compensation via performance awards on February 12, 2020. The filing also details multiple past three‑month sales by entities TPC RP EPA1 LLC and TPC RP 2021 LLC, including individual transactions of up to 69,665 shares for $2,938,636.90 in gross proceeds.
RPRX filed a notice of proposed insider sales of common stock under Rule 144. The filing covers up to 108,424 common shares to be sold through Goldman Sachs & Co. LLC on the NASD, with an aggregate market value of $4,592,840.64 and 427,247,489 shares outstanding.
The seller reports acquiring 102,581 shares on 06/16/2020 from the issuer in a private transaction and 5,843 shares on 02/12/2020 as compensation through performance awards. The notice also lists multiple recent common stock sales over the past three months by TPC RP EPA1 LLC and TPC RP 2021 LLC, each generating six-figure gross proceeds.
Royalty Pharma plc executive Marshall Urist reported an automatic share sale under a pre-arranged trading plan. On January 30, 2026, an entity listed as Sandy Lamm LLC sold 20,000 Class A Ordinary Shares at a weighted average price of $41.0905 per share under a Rule 10b5-1 plan adopted on September 16, 2025.
After this sale, accounts associated with Urist continued to hold 19,020 Class A Ordinary Shares indirectly through an IRA and 7,398 Class A Ordinary Shares directly. The filing also notes additional exchangeable partnership and Class E ordinary share interests that could convert into Class A Ordinary Shares, subject to vesting conditions.